WallStreetZenWallStreetZen

NYSE: CRL
Charles River Laboratories International Inc Stock Forecast, Predictions & Price Target

OverviewForecast
EarningsDividendOwnership

Analyst price target for CRL

Based on 13 analysts offering 12 month price targets for Charles River Laboratories International Inc.
Min Forecast
$240.00-2.08%
Avg Forecast
$301.00+22.81%
Max Forecast
$400.00+63.21%

Should I buy or sell CRL stock?

Based on 14 analysts offering ratings for Charles River Laboratories International Inc.
Strong Buy
Strong Buy
8 analysts 57.14%
Buy
3 analysts 21.43%
Hold
3 analysts 21.43%
Sell
0 analysts 0%
Strong Sell
0 analysts 0%

Be the first to know when Wall Street analysts revise their CRL stock forecasts and price targets.

CRL stock forecasts by analyst

Analyst / FirmRatingActionPrice TargetUpside/DownsideDateAnalyst Color
Baird
Bottom 26%
26
BuyMaintains$285.00+16.28%2023-01-11
JP Morgan
Top 20%
81
Strong BuyMaintains$275.00+12.20%2022-11-03
Credit Suisse
Top 7%
94
BuyMaintains$280.00+14.24%2022-11-03
Morgan Stanley
Top 3%
98
HoldMaintains$241.00-1.67%2022-11-03
Jefferies
Top 5%
96
Strong BuyUpgrades$240.00-2.08%2022-09-30
Credit Suisse
Bottom 13%
13
BuyInitiates Coverage On$285.00+16.28%2022-08-25
Wells Fargo
Top 23%
78
Strong BuyMaintains$300.00+22.40%2022-08-16
Morgan Stanley
Bottom 5%
5
HoldDowngrades$250.00+2.00%2022-08-04
Deutsche Bank
Top 35%
66
Strong BuyMaintains$290.00+18.32%2022-07-14
Guggenheim
Top 8%
93
HoldInitiates Coverage OnN/AN/A2022-05-24

1 of 2

Forecast return on equity

Is CRL forecast to generate an efficient return?
Company
N/A
Industry
0.2%
Market
12.46%

Forecast return on assets

Is CRL forecast to generate an efficient return on assets?
Company
N/A
Industry
0.14%

CRL earnings per share forecast

What is CRL's earnings per share in the next 3 years based on estimates from 8 analysts?
Avg 1 year Forecast
$12.38+43.62%
Avg 2 year Forecast
$14.51+68.33%
Avg 3 year Forecast
$15.76+82.83%
CRL's earnings are forecast to... subscribe to Premium to read more.
Forecast High Earnings Growth Forecast

CRL revenue forecast

What is CRL's revenue in the next 3 years based on estimates from 6 analysts?
Avg 1 year Forecast
$4.2B+12.36%
Avg 2 year Forecast
$4.7B+24.48%
Avg 3 year Forecast
$5.1B+33.95%
CRL's revenue is forecast to... subscribe to Premium to read more.
Forecast High Revenue Growth Forecast

CRL earnings growth forecast

How is CRL forecast to perform vs Diagnostics & Research companies and vs the US market?
Company
23.45%
Industry
20.75%
Market
24.23%
CRL's earnings are forecast to... subscribe to Premium to read more.
Forecast Earnings Growth vs Industry Forecast
CRL's earnings are forecast to... subscribe to Premium to read more.
Forecast Earnings Growth vs Market Forecast
CRL's earnings are forecast to... subscribe to Premium to read more.
Forecast Earnings Growth vs Savings Rate Forecast

CRL revenue growth forecast

How is CRL forecast to perform vs Diagnostics & Research companies and vs the US market?
Company
10.6%
Industry
9.7%
Market
9.31%
CRL's revenues are forecast to... subscribe to Premium to read more.
Forecast Revenue Growth vs Industry Forecast
CRL's revenues are forecast to... subscribe to Premium to read more.
Forecast Revenue Growth vs Market Forecast

CRL vs Diagnostic & Research Stocks

TickerPricePrice TargetUp/downsideConsensus
CRL$245.09$301.00+22.81%Strong Buy
EXAS$67.48$65.20-3.38%Buy
QGEN$49.30$55.00+11.56%Strong Buy
PHG$16.99N/AN/AHold
DGX$145.63$147.43+1.24%Hold
View Top Diagnostic & Research Stocks

Charles River Laboratories International Stock Forecast FAQ

Is Charles River Laboratories International Stock a good buy in 2023, according to Wall Street analysts?

The consensus among 14 Wall Street analysts covering (NYSE: CRL) stock is to Strong Buy CRL stock.

Out of 14 analysts, 8 (57.14%) are recommending CRL as a Strong Buy, 3 (21.43%) are recommending CRL as a Buy, 3 (21.43%) are recommending CRL as a Hold, 0 (0%) are recommending CRL as a Sell, and 0 (0%) are recommending CRL as a Strong Sell.

If you're new to stock investing, here's how to buy Charles River Laboratories International stock.

What is CRL's earnings growth forecast for 2023-2025?

(NYSE: CRL) Charles River Laboratories International's forecast annual earnings growth rate of 23.45% is forecast to beat the US Diagnostics & Research industry's average forecast earnings growth rate of 20.75%, and while it is not forecast to beat the US market's average forecast earnings growth rate of 24.23%.

Charles River Laboratories International's earnings in 2023 is $436,394,000.On average, 8 Wall Street analysts forecast CRL's earnings for 2023 to be $629,877,761, with the lowest CRL earnings forecast at $585,104,544, and the highest CRL earnings forecast at $669,054,326. On average, 5 Wall Street analysts forecast CRL's earnings for 2024 to be $738,249,299, with the lowest CRL earnings forecast at $699,072,733, and the highest CRL earnings forecast at $788,110,381.

In 2025, CRL is forecast to generate $801,847,619 in earnings, with the lowest earnings forecast at $801,847,619 and the highest earnings forecast at $801,847,619.

What is CRL's revenue growth forecast for 2023-2025?

(NYSE: CRL) Charles River Laboratories International's forecast annual revenue growth rate of 10.6% is forecast to beat the US Diagnostics & Research industry's average forecast revenue growth rate of 9.7%, and and it is also forecast to beat the US market's average forecast revenue growth rate of 9.31%.

Charles River Laboratories International's revenue in 2023 is $3,781,267,000.On average, 6 Wall Street analysts forecast CRL's revenue for 2023 to be $216,168,349,262, with the lowest CRL revenue forecast at $211,184,581,392, and the highest CRL revenue forecast at $220,575,967,231. On average, 5 Wall Street analysts forecast CRL's revenue for 2024 to be $239,477,845,843, with the lowest CRL revenue forecast at $234,472,251,030, and the highest CRL revenue forecast at $243,991,545,810.

In 2025, CRL is forecast to generate $257,710,059,585 in revenue, with the lowest revenue forecast at $257,710,059,585 and the highest revenue forecast at $257,710,059,585.

What is CRL's forecast return on assets (ROA) for 2023-2026?

(NYSE: CRL) forecast ROA is N/A, which is lower than the forecast US Diagnostics & Research industry average of 0.14%.

What is CRL's Price Target?

According to 13 Wall Street analysts that have issued a 1 year CRL price target, the average CRL price target is $301.00, with the highest CRL stock price forecast at $400.00 and the lowest CRL stock price forecast at $240.00.

On average, Wall Street analysts predict that Charles River Laboratories International's share price could reach $301.00 by Jan 11, 2024. The average Charles River Laboratories International stock price prediction forecasts a potential upside of 22.81% from the current CRL share price of $245.09.

What is CRL's Earnings Per Share (EPS) forecast for 2023-2025?

(NYSE: CRL) Charles River Laboratories International's current Earnings Per Share (EPS) is $8.62. On average, analysts forecast that CRL's EPS will be $12.38 for 2023, with the lowest EPS forecast at $11.50, and the highest EPS forecast at $13.15. On average, analysts forecast that CRL's EPS will be $14.51 for 2024, with the lowest EPS forecast at $13.74, and the highest EPS forecast at $15.49. In 2025, CRL's EPS is forecast to hit $15.76 (min: $15.76, max: $15.76).

What is CRL's forecast return on equity (ROE) for 2023-2026?

(NYSE: CRL) forecast ROE is N/A, which is considered weak.
©2023 WallStreetZen
Company
AboutBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsHelp GuidesContactTwitterYouTube
Stock Tools
Top Performing AnalystsStock ScreenerStock ForecastTrending StocksStrong Buy StocksHighest Earnings StocksBest Dividend Paying StocksStatisticsStock Market SectorsStock Market IndustriesHow to Buy Stocks Online
Stock Ideas
Buy The DipBiggest Stock Gainers TodayBiggest Stock Losers Today52 Week High Stocks52 Week Low StocksMost Active Stocks TodayMost Undervalued StocksBest Penny Stocks to Buy NowBest Stocks Under $5Best Stocks Under $10
WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.

Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.